Munich - Delayed Quote • EUR TG Therapeutics Inc (NKB2.MU) Follow Add holdings 30.17 -0.03 (-0.08%) At close: May 15 at 8:00:15 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for NKB2.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: NKB2.MU View More All News Press Releases SEC Filings TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... Q1 2025 TG Therapeutics Inc Earnings Call Why TG Therapeutics Stock Was Tumbling Today TG Therapeutics (TGTX) Lags Q1 Earnings Estimates TG Therapeutics: Q1 Earnings Snapshot TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings